CompletedPhase 4NCT01419249
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
Studying Turner syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Principal Investigator
- Gilles Della CorteMerck Serono S.A. , Geneva, Switzerland
- Intervention
- Blood sampling(other)
- Enrollment
- 458 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2012
Study locations (30)
- Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina
- Hospital de Pediatria Garrahan, Buenos Aires, Argentina
- Hospital de Niños de la Santisima Trinidad, Córdoba, Argentina
- University of Calgary - Alberta Children's Hospital, Calgary, Canada
- CHU Sainte Justine Montréal, Montreal, Canada
- Centre Hospitalier Universitaire de Sherbrooke - Fleurimont, Sherbrooke, Canada
- British Columbia Children's Hospital, Vancouver, Canada
- Fakultní nemocnice Brno, Brno, Czechia
- University Hospital Hradec Kralove, Hradec Králové, Czechia
- Faculty Hospital, Olomouc, Czechia
- University Hospital Praha Motol, Prague, Czechia
- Centre d'Endocrinologie Pédiatrique, Bordeaux, France
- CHU Bordeaux - Hopital pédiatrique Pellegrin, Bordeaux, France
- Hôpital Femme-Mère-Enfant, Bron, France
- University of Cologne Children's Hospital, Cologne, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
Merck Serono S.A., Geneva
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01419249 on ClinicalTrials.govOther trials for Turner syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502586Turner Syndrome: Genetic ConsiderationsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- RECRUITINGPHASE3NCT07221851Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersAscendis Pharma A/S
- RECRUITINGNCT07344012Parental Project Amongst 93 Patients With Turner SyndromeUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06834594Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner SyndromeChildren's Mercy Hospital Kansas City
- RECRUITINGNCT06507007Genetic and Epigenetic Background of Inner Ear Dysfunction in Turner SyndromeGødstrup Hospital
- RECRUITINGNCT06794190Characterization of Hepatopathy in Turner Syndrome: Analysis of DeterminantsIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06668805A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentBioMarin Pharmaceutical
- RECRUITINGPHASE2NCT05849389Vosoritide for Short Stature in Turner SyndromeRoopa Kanakatti Shankar, MBBS, MS